WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype

Current Opinion in Allergy and Clinical Immunology

Volumn 3, Issue 6, 2003, Pages 427-436

  Imai, Kohsuke ^a   Nonoyama, Shigeaki ^b   Ochs, Hans D ^c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Actin cytoskeleton; Autoimmune disease; Congenital neutropenia; Congenital thrombocytopenia; Gene therapy; Genotype phenotype correlation; Primary immunodeficiency; Small G protein; Wiskott Aldrich syndrome

Indexed keywords

ACTIN; ACTIN RELATED PROTEIN 2; ACTIN RELATED PROTEIN 3; PROTEIN CDC42; WISKOTT ALDRICH SYNDROME PROTEIN; PROTEIN; WAS PROTEIN, HUMAN;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ATOPIC DERMATITIS; CANCER; CELL INTERACTION; CELL MOTILITY; CELL STRAIN COS7; CONTROLLED STUDY; CYTOSKELETON; DAUDI CELL; DENDRITIC CELL; GENE MUTATION; GENE THERAPY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LEUKEMIA CELL LINE; LYMPHOCYTE; MACROPHAGE; MISSENSE MUTATION; MONOCYTE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REVIEW; T LYMPHOCYTE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER; ANIMAL; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHENOTYPE;

ANIMALS; DENDRITIC CELLS; GENE THERAPY; HUMANS; KILLER CELLS, NATURAL; MACROPHAGES; MONOCYTES; MUTATION; PHENOTYPE; PROTEINS; T-LYMPHOCYTES; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 2942717809     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200312000-00003     Document Type: Review

References (87)

1. Ochs HD, Rosen FS. The Wiskott-Aldrich syndrome. In: Ochs HD, Smith CIE, Puck JM, editors. Primary immunodeficiency diseases: a molecular and genetic approach. Oxford University Press: Oxford; 1999. pp. 292-305.
2. Bach FH, Albertini RJ, Joo P, et al. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968; 2:1364-1366.
3. Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 2001; 97:1598-1603.
4. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994; 125:876-885.
5. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994; 78:635-644 [published erratum in Cell 1994; 79:922].
6. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994; 78:635-644 [published erratum in Cell 1994; 79:922].
7. Schwarz K. WASPbase: a database of WAS- and XLT-causing mutations. Immunol Today 1996; 17:496-502.
8. Zhu Q, Zhang M, Blaese RM, et al. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. Blood 1995; 86:3797-3804.
9. Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet 1995; 9:414-417.
10. Canales ML, Mauer AM. Sex-linked hereditary thrombocytopenia as a variant of Wiskott-Aldrich syndrome. N Engl J Med 1967; 277:899-901.
11. Notarangelo LD, Mazza C, Giliani S, et al. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood 2002; 99:2268-2269. This paper describes two families with intermittent thrombocytopenia due to missense mutations of the WASP gene. This is the mildest phenotype of WASP gene mutations, and expands the clinical spectrum of the disease.
12. Ancliff PJ, Blundell MP, Gale RE, et al. Activating mutations in the Wiskott-Aldrich syndrome protein may define a sub-group of severe congenital neutropenia (SCN) with specific and unusual laboratory features. American Society of Hematology 43rd Annual Meeting; Orlando, Florida; 2001.
13. Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001; 27:313-317.
14. Parolini O, Ressmann G, Haas OA, et al. X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med 1998; 338:291-295.
15. Inoue H, Kurosawa H, Nonoyama S, et al. X-linked thrombocytopenia in a girl. Br J Haematol 2002; 118:1163-1165. This is a report of a rare case of XLT in a female with heterozygous mutation of the WASP gene.
16. Lutskiy MI, Sasahara Y, Kenney DM, et al. Wiskott-Aldrich syndrome in a female. Blood 2002; 100:2763-2768. This is a report of a rare case of WAS in a female with heterozygous mutation of the WASP gene. Analysis of WASP expression in her blood cells indicates that activation and maturation of T lymphocytes is associated with preferential expansion of WASP-positive cells.
17. Zhu Q, Christie JR, Tyler EO, et al. X-chromosome inactivation in symptomatic carrier females of X-linked thrombocytopenia. Clin Immunol 2002; 103:S129-S130. This describes symptomatic carriers for XLT.
18. Miki H, Miura K, Takenawa T. N-WASP a novel actin-depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kinases. EMBO J 1996; 15:5326-5335.
19. Thrasher AJ. WASp in immune-system organization and function. Nat Rev Immunol 2002; 2:635-646. This is a very detailed review on the biological properties of WASP and related proteins, and offers a nice overview of the cellular defects associated with WASP gene mutations.
20. Takenawa T, Miki H. WASP and WAVE family proteins: key molecules for rapid rearrangement of cortical actin filaments and cell movement. J Cell Sci 2001; 114:1801-1809.
21. Caron E. Regulation of Wiskott-Aldrich syndrome protein and related molecules. Curr Opin Cell Biol 2002; 14:82-87. This is a review of WASP family proteins focused on molecular aspects.
22. Kim AS, Kakalis LT, Abdul-Manan N, et al. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 2000; 404:151-158.
23. Weaver AM, Young ME, Lee WL, Cooper JA. Integration of signals to the Arp2/3 complex. Curr Opin Cell Biol 2003; 15:23-30. This review focused on the Arp2/3 complex and its regulation of actin cytoskeleton.
24. Higgs HN, Pollard TD. Activation by Cdc42 and PIP(2) of Wiskott-Aldrich syndrome protein (WASp) stimulates actin nucleation by Arp2/3 complex. J Cell Biol 2000; 150:1311-1320.
25. Rohatgi R, Nollau P, Ho HY, et al. Nck and phosphatidylinositol 4,5-bisphosphate synergistically activate actin polymerization through the N-WASP-Arp2/3 pathway. J Biol Chem 2001; 276:26448-26452.
26. Rozelle AL, Machesky LM, Yamamoto M, et al. Phosphatidylinositol 4,5-bisphosphate induces actin-based movement of raft-enriched vesicles through WASP-Arp2/3. Curr Biol 2000; 10:311-320.
27. Guinamard R, Aspenstrom P, Fougereau M, et al. Tyrosine phosphorylation of the Wiskott-Aldrich syndrome protein by Lyn and Btk is regulated by CDC42. FEBS Lett 1998; 434:431-436.
28. Banin S, Truong O, Katz DR, et al. Wiskott-Aldrich syndrome protein (wasp) is a binding partner for c-src family protein-tyrosine kinases. Curr Biol 1996; 6:981-988.
29. Bunnell SC, Henry PA, Kollun R, et al. Identification of itk/tsk src homology 3 domain ligands. J Biol Chem 1996; 271:25646-25656.
30. Finan PM, Soames CJ, Wilson L, et al. Identification of regions of the Wiskott-Aldrich syndrome protein responsible for association with selected src homology 3 domains. J Biol Chem 1996; 271:26291-26295.
31. Cory G, Maccarthymorrogh L, Banin S, et al. Evidence that the Wiskott-Aldrich syndrome protein may be involved in lymphoid cell signaling pathways. J Immunol 1996; 157:3791-3795.
32. Scott MP, Zappacosta F, Kim EY, et al. Identification of novel SH3 domain ligands for the Src family kinase Hck: Wiskott-Aldrich syndrome protein (WASP), WASP-interacting protein (WIP), and ELMO1. J Biol Chem 2002; 277:28238-28246. This paper demonstrates that WASP and WIP are major binding partners of Hck, a Src-family tyrosine kinase that plays a major role in regulating cell migration and integrin-mediated signal transduction.
33. Ramesh N, Anton IM, Hartwig JH, Geha RS. WIP, a protein associated with Wiskott-Aldrich syndrome protein, induces actin polymerization and redistribution in lymphoid cells. Proc Natl Acad Sci U S A 1997; 94:14671-14676.
34. Rivero-Lezcano OM, Marcilla A, Sameshima JH, Robbins KC. Wiskott-Aldrich syndrome protein physically associates with Nck through Src homology 3 domains. Mol Cell Biol 1995; 15:5725-5731.
35. Wu Y, Spencer SD, Lasky LA. Tyrosine phosphorylation regulates the SH3-mediated binding of the Wiskott-Aldrich syndrome protein to PSTPIP, a cytoskeletal-associated protein. J Biol Chem 1998; 273:5765-5770.
36. McGavin MK, Badour K, Hardy LA, et al. The intersectin 2 adaptor links Wiskott Aldrich Syndrome protein (WASp)-mediated actin polymerization to T cell antigen receptor endocytosis. J Exp Med 2001; 194:1777-1787.
37. Symons M, Derry JM, Karlak B, et al. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell 1996; 84:723-734.
38. Aspenstrom P, Lindberg U, Hall A. Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome. Curr Biol 1996; 6:70-75.
39. Kolluri R, Tolias KF, Carpenter CL, et al. Direct interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42. Proc Natl Acad Sci U S A 1996; 93:5615-5618.
40. Miki H, Takenawa T. Direct binding of the verprolin-homology domain in N-Wasp to actin is essential for cytoskeletal reorganization. Biochem Biophys Res Commun 1998; 243:73-78.
41. Machesky LM, Insall RH. Scarl and the related Wiskott-Aldrich syndrome protein, WASP, regulate the actin cytoskeleton through the Arp2/3 complex. Curr Biol 1998; 8:1347-1356.
42. Suetsugu S, Miki H, Takenawa T. The essential role of profilin in the assembly of actin for microspike formation. EMBO J 1998; 17:6516-6526.
43. Castellano F, Le Clainche C, Patin D, et al. A WASp-VASP complex regulates actin polymerization at the plasma membrane. EMBO J 2001; 20:5603-5614.
44. Imai K, Nonoyama S, Miki H, et al. The pleckstrin homology domain of the Wiskott-Aldrich syndrome protein is involved in the organization of actin cytoskeleton. Clin Immunol 1999; 92:128-137.
45. Volkman BF, Prehoda KE, Scott JA, et al. Structure of the N-WASP EVH1 domain-WIP complex: insight into the molecular basis of Wiskott-Aldrich syndrome. Cell 2002; 111:565-576. This study analyzes in detail the biochemistry and structure of the WASP-WIP interaction, and evaluates the putative effect that various missense mutations in the WH1 domain of WASP have on this interaction.
46. Baba Y, Nonoyama S, Matsushita M, et al. Involvement of Wiskott-Aldrich syndrome protein in B-cell cytoplasmic tyrosine kinase pathway. Blood 1999; 93:2003-2012.
47. Cory GO, Garg R, Cramer R, Ridley AJ. Phosphorylation of tyrosine 291 enhances the ability of WASp to stimulate actin polymerization and filopodium formation: Wiskott-Aldrich syndrome protein. J Biol Chem 2002; 277:45115-45121. This study illustrates the important role of phosphorylation of Tyr291 of WASP in regulating formation of cellular podosomes and filopodia.
48. Cory GO, Cramer R, Blanchoin L, Ridley AJ. Phosphorylation of the WASP-VCA domain increases its affinity for the Arp2/3 complex and enhances actin polymerization by WASP. Mol Cell 2003; 11:1229-1239. This study demonstrates the phosphorylation of serine within the cofilin homology domain of WASP and its effect on the actin polymerization activity of WASP via Arp2/3 complex.
49. Ponting CP, Phillips C. Identification of homer as a homologue of the Wiskott-Aldrich syndrome protein suggests a receptor-binding function for WH1 domains. J Mol Med 1997; 75:769-771.
50. Prehoda KE, Lee DJ, Lim WA. Structure of the enabled/VASP homology 1 domain-peptide complex: a key component in the spatial control of actin assembly. Cell 1999; 97:471-480.
51. Rong SB, Vihinen M. Structural basis of Wiskott-Aldrich syndrome causing mutations in the WH1 domain. J Mol Med 2000; 78:530-537.
52. Martinez-Quiles N, Rohatgi R, Anton IM, et al. WIP regulates N-WASP-mediated actin polymerization and filopodium formation. Nat Cell Biol 2001; 3:484-491.
53. Anton IM, Saville SP, Byrne MJ, et al. WIP participates in actin reorganization and ruffle formation induced by PDGF. J Cell Sci 2003; 116:2443-2451.
54. Benesch S, Lommel S, Steffen A, et al. Phosphatidylinositol 4,5-biphosphate (PIP2)-induced vesicle movement depends on N-WASP and involves Nck, WIP, and Grb2. J Biol Chem 2002; 277:37771-37776.
55. Sasahara Y, Rachid R, Byrne MJ, et al. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol Cell 2002; 10:1269-1281. This paper demonstrates that the constitutive interaction between WASP and WIP is released (permitting WASP-dependent activation of the Arp2/3 complex) upon formation of a macromolecular complex, which also includes Crk1. This complex is recruited to the immunological synapse by ZAP-70. This results in phosphorylation of WIP, and subsequent activation of WASP by GTP-bound Cdc42.
56. Anton IM, de la Fuente MA, Sims TN, et al. WIP deficiency reveals a differential role for WIP and the actin cytoskeleton in T and B cell activation. Immunity 2002; 16:193-204. This is a report of WIP knockout mice. The authors focus on the description of T- and B-lymphocyte development and function in WIP-deficient mice. WIP-deficient T cells have impaired activation following TCR stimulation. WIP-deficient B cells show hyperreactivity to B-cell receptor stimulation. T and B cells have a profound defect in the subcortical actin filament network. The authors propose that WIP is important for immunological synapse formation and T-cell activation.
57. Snapper SB, Rosen FS, Mizoguchi E, et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 1998; 9:81-91.
58. Zhang J, Shehabeldin A, da Cruz LA, et al. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J Exp Med 1999; 190:1329-1342.
59. Badour K, Zhang J, Shi F, et al. The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse. Immunity 2003; 18:141-154. The authors show that CD2 crosslinking induces formation of a macromolecular complex that includes CD2, CD2AP, PSTPIP1, and WASP. WASP directly binds to PSTPIP1 which binds to CD2, CD2AP. This complex is recruited to the immunological synapse and induces actin nucleation. CD2-induced actin polymerization is abrogated in WAS.
60. Cannon JL, Labno CM, Bosco G, et al. Wasp recruitment to the T cell:APC contact site occurs independently of Cdc42 activation. Immunity 2001; 15:249-259.
61. Zeng R, Cannon JL, Abraham RT, et al. SLP-76 coordinates Nck-dependent Wiskott-Aldrich syndrome protein recruitment with Vav-1/Cdc42-dependent Wiskott-Aldrich syndrome protein activation at the T cell-APC contact site. J Immunol 2003; 171:1360-1368. This study shows the different molecules that participate in the membrane localization and activation of WASP at the immunological synapse. Vav1 is needed to activate Cdc42 as a small G protein enhancing factor that leads to the activation of WASP. Nck is needed to recruit WASP to the immunological synapse. Nck binds to SLP-76, which functions as a scaffold.
62. Dupre L, Aiuti A, Trifari S, et al. Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity 2002; 17:157-166. This study shows that WASP is rapidly recruited to the immunological synapse during T-cell activation, and demonstrates that WAS is associated with reduced basal levels, and failure to upregulate lipid rafts following TCR engagement.
63. Molina IJ, Sancho J, Terhorst C, et al. T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J Immunol 1993; 151:4383-4390.
64. Orange JS, Ramesh N, Remold-O'Donnell E, et al. Wiskoft-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A 2002; 99:11351-11356. In this paper, the authors demonstrate that WASP is expressed in human natural killer cells, and is recruited to natural killer cell-activating immunological synapses. They also show the compensatory increase in natural killer cell population in WAS patients.
65. Haddad E, Zugaza JL, Louache F, et al. The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. Blood 2001; 97:33-38.
66. Yarar D, D'Alessio JA, Jeng RL, Welch MD. Motility determinants in WASP family proteins. Mol Biol Cell 2002; 13:4045-4059. In this study, the authors show that the VCA region of WASP is the minimal part of the molecule required both for stimulating acting nucleation and for cell motility.
67. Leverrier Y, Lorenzi R, Blundell MP, et al. Cutting edge: the Wiskott-Aldrich syndrome protein is required for efficient phagocytosis of apoptotic cells. J Immunol 2001; 166:4831-4834.
68. Jones GE, Zicha D, Dunn GA, et al. Restoration of podosomes and chemotaxis in Wiskott-Aldrich syndrome macrophages following induced expression of WASp. Int J Biochem Cell Biol 2002; 34:806-815. This is a study of chemotaxis of WASP-deficient macrophages. The chemotaxis, cell morphology and ability to form podosome was restored by exogenous WASP expression.
69. Knutsen AP, Steffen M, Wassmer K, Wall DA. Umbilical cord blood transplantation in Wiskott Aldrich syndrome. J Pediatr 2003; 142:519-523. This is a report of successful unrelated umbilical cord blood transplantation in three WAS patients.
70. Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood (in press).
71. Huang MM, Tsuboi S, Wong A, et al. Expression of human Wiskott-Aldrich syndrome protein in patients' cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins. Gene Ther 2000; 7:314-320.
72. Candotti F, Facchetti F, Blanzuoli L, et al. Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott-Aldrich syndrome patients carrying 'null' mutations. Gene Therapy 1999; 6:1170-1174.
73. Strom TS, Gabbard W, Kelly PF, et al. Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein. Gene Ther 2003; 10:803-809. In this study gene therapy was performed on primary T cells of WAS patients. The authors show the feasibility of gene transfer without toxic effect on T cells.
74. Wada T, Jagadeesh GJ, Nelson DL, Candotti F. Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction. Hum Gene Ther 2002; 13:1039-1046. Gene transfer has been performed in HTLV-1 transformed T-cell lines derived from WAS patients.
75. Klein C, Nguyen D, Liu CH, et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood 2003; 101:2159-2166. This is the first report of correction of T-cell abnormalities of WASP-deficient mice by gene transfer. Furthermore, by using competitive repopulation experiments, the authors have shown that 9ene gene-corrected cells have a selected advantage over WASP-null cells in repopulating secondary lymphoid organs.
76. Wada T, Schurman SH, Otsu M, et al. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci U S A 2001; 98:8697-8702.
77. Ariga T, Kondoh T, Yamaguchi K, et al. Spontaneous in vivo reversion of an inherited mutation in the Wiskott-Aldrich syndrome. J Immunol 2001; 166:5245-5249.
78. Wengler GS, Notarangelo LD, Berardelli S, et al. High prevalence of nonsense, frame shift, and splice-site mutations in 16 patients with full-blown Wiskott-Aldrich syndrome. Blood 1995; 86:3648-3654.
79. Zhu QL, Watanabe C, Liu T, et al. Wiskot-Aldrich-syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 1997; 90:2680-2689.
80. Lemahieu V, Gastier JM, Francke U. Novel mutations in the Wiskott-Aldrich syndrome protein gene and their effects on transcriptional, translational, and clinical phenotypes. Hum Mutat 1999; 14:54-66.
81. Greer WL, Shehabeldin A, Schulman J, et al. Identification of wasp mutations, mutation hotspots and genotype-phenotype disparities in 24 patients with the Wiskott-Aldrich syndrome. Hum Genet 1996; 98:685-690.
82. Schindelhauer D, Weiss M, Hellebrand H, et al. Wiskott-Aldrich syndrome: no strict genotype-phenotype correlations but clustering of missense mutations in the amino-terminal part of the wasp gene product. Hum Genet 1996; 98:68-76.
83. Imai K. WASPbase. Updated 1 January 2002. http://www.tmd.ac.jp/med/ped/ wasp/WASPbase.html. [Accessed 1 August 2003] This is a database of WASP gene mutations and WAS phenotype from the literature and includes over 300 patients. This database is different from a previously published WASPbase (Schwarz [6])
84. Ochs HD. The Wiskott-Aldrich syndrome. Isr Med Assoc J 2002; 4:379-384. This paper has the updated scoring system with detailed explanation.
85. Stewart DM, Tian L, Nelson DL. Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein. J Immunol 1999; 162:5019-5024.
86. Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003; 111:e622-e627. This is the largest survey of classical WAS patients from a single center which focuses on the incidence of autoimmune diseases. XLT patients were excluded from this study.
87. Schurman SH, Candotti F. Autoimmunity in Wiskott-Aldrich syndrome. Curr Opin Rheumatol 2003; 15:446-453. This is a comprehensive review of the relationship between WAS and autoimmune diseases.